169 related articles for article (PubMed ID: 35493690)
1. Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma.
Nakagawa M; Yamaguchi M; Endo M; Machida Y; Hattori A; Tanzawa F; Tsutsumi S; Kitabayashi I; Kawai A; Nakatani F
J Bone Oncol; 2022 Jun; 34():100430. PubMed ID: 35493690
[TBL] [Abstract][Full Text] [Related]
2. Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.
Fathi AT; Nahed BV; Wander SA; Iafrate AJ; Borger DR; Hu R; Thabet A; Cahill DP; Perry AM; Joseph CP; Muzikansky A; Chi AS
Oncologist; 2016 Feb; 21(2):214-9. PubMed ID: 26834160
[TBL] [Abstract][Full Text] [Related]
3. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC
PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of IDH mutations in chondrosarcoma.
Nakagawa M; Sekimizu M; Endo M; Kobayashi E; Iwata S; Fukushima S; Yoshida A; Kitabayashi I; Ichikawa H; Kawai A; Nakatani F
J Orthop Sci; 2022 Nov; 27(6):1315-1322. PubMed ID: 34531086
[TBL] [Abstract][Full Text] [Related]
5. In Vivo Imaging of Glutamine Metabolism to the Oncometabolite 2-Hydroxyglutarate in IDH1/2 Mutant Tumors.
Salamanca-Cardona L; Shah H; Poot AJ; Correa FM; Di Gialleonardo V; Lui H; Miloushev VZ; Granlund KL; Tee SS; Cross JR; Thompson CB; Keshari KR
Cell Metab; 2017 Dec; 26(6):830-841.e3. PubMed ID: 29056515
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma.
Nakagawa M; Nakatani F; Matsunaga H; Seki T; Endo M; Ogawara Y; Machida Y; Katsumoto T; Yamagata K; Hattori A; Fujita S; Aikawa Y; Ishikawa T; Soga T; Kawai A; Chuman H; Yokoyama N; Fukushima S; Yahiro K; Kimura A; Shimada E; Hirose T; Fujiwara T; Setsu N; Matsumoto Y; Iwamoto Y; Nakashima Y; Kitabayashi I
Oncogene; 2019 Oct; 38(42):6835-6849. PubMed ID: 31406254
[TBL] [Abstract][Full Text] [Related]
7. Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms.
Babakoohi S; Lapidus RG; Faramand R; Sausville EA; Emadi A
Appl Immunohistochem Mol Morphol; 2017; 25(5):334-337. PubMed ID: 26945443
[TBL] [Abstract][Full Text] [Related]
8. The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.
Tinoco G; Wilky BA; Paz-Mejia A; Rosenberg A; Trent JC
Am Soc Clin Oncol Educ Book; 2015; ():e648-55. PubMed ID: 25993236
[TBL] [Abstract][Full Text] [Related]
9. Mutant IDH1 Depletion Downregulates Integrins and Impairs Chondrosarcoma Growth.
Li L; Hu X; Eid JE; Rosenberg AE; Wilky BA; Ban Y; Sun X; Galoian K; DeSalvo J; Yue J; Chen XS; Blonska M; Trent JC
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31935911
[TBL] [Abstract][Full Text] [Related]
10. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.
Pope WB; Prins RM; Albert Thomas M; Nagarajan R; Yen KE; Bittinger MA; Salamon N; Chou AP; Yong WH; Soto H; Wilson N; Driggers E; Jang HG; Su SM; Schenkein DP; Lai A; Cloughesy TF; Kornblum HI; Wu H; Fantin VR; Liau LM
J Neurooncol; 2012 Mar; 107(1):197-205. PubMed ID: 22015945
[TBL] [Abstract][Full Text] [Related]
11. Preoperative Determination of Isocitrate Dehydrogenase Mutation in Gliomas Using Spectral Editing MRS: A Prospective Study.
Nguyen TB; Melkus G; Taccone M; Moldovan ID; Ghinda D; Gotfrit R; Torres CH; Zakhari N; Chakraborty S; Woulfe J; Jansen G; McInnes MD; Thornhill RE; Cameron I; AlKherayf F
J Magn Reson Imaging; 2021 Feb; 53(2):416-426. PubMed ID: 32940938
[TBL] [Abstract][Full Text] [Related]
12. Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma.
Radoul M; Hong D; Gillespie AM; Najac C; Viswanath P; Pieper RO; Costello JF; Luchman HA; Ronen SM
Metabolites; 2021 Feb; 11(2):. PubMed ID: 33668509
[TBL] [Abstract][Full Text] [Related]
13. Beyond the Influence of
Venneker S; Kruisselbrink AB; Baranski Z; Palubeckaite I; Briaire-de Bruijn IH; Oosting J; French PJ; Danen EHJ; Bovée JVMG
Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33266275
[TBL] [Abstract][Full Text] [Related]
14. Targeting isocitrate dehydrogenase (IDH) in cancer.
Fujii T; Khawaja MR; DiNardo CD; Atkins JT; Janku F
Discov Med; 2016 May; 21(117):373-80. PubMed ID: 27355333
[TBL] [Abstract][Full Text] [Related]
15.
Venneker S; Bovée JVMG
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509266
[TBL] [Abstract][Full Text] [Related]
16. Magnetic Resonance Spectroscopy for Detection of 2-Hydroxyglutarate as a Biomarker for IDH Mutation in Gliomas.
Leather T; Jenkinson MD; Das K; Poptani H
Metabolites; 2017 Jun; 7(2):. PubMed ID: 28629182
[TBL] [Abstract][Full Text] [Related]
17. 2-hydroxyglutarate as a magnetic resonance biomarker for glioma subtyping.
Esmaeili M; Vettukattil R; Bathen TF
Transl Oncol; 2013 Apr; 6(2):92-8. PubMed ID: 23544162
[TBL] [Abstract][Full Text] [Related]
18. Molecular Imaging of Metabolic Reprograming in Mutant IDH Cells.
Viswanath P; Chaumeil MM; Ronen SM
Front Oncol; 2016; 6():60. PubMed ID: 27014635
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid 2-hydroxyglutarate (2-HG) as a monitoring biomarker for IDH-mutant gliomas.
Riviere-Cazaux C; Lacey JM; Carlstrom LP; Laxen WJ; Munoz-Casabella A; Hoplin MD; Ikram S; Zubair AB; Andersen KM; Warrington AE; Decker PA; Kaufmann TJ; Campian JL; Eckel-Passow JE; Kizilbash SH; Tortorelli S; Burns TC
medRxiv; 2023 Mar; ():. PubMed ID: 36909488
[TBL] [Abstract][Full Text] [Related]
20. Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.
de la Fuente MI; Young RJ; Rubel J; Rosenblum M; Tisnado J; Briggs S; Arevalo-Perez J; Cross JR; Campos C; Straley K; Zhu D; Dong C; Thomas A; Omuro AA; Nolan CP; Pentsova E; Kaley TJ; Oh JH; Noeske R; Maher E; Choi C; Gutin PH; Holodny AI; Yen K; DeAngelis LM; Mellinghoff IK; Thakur SB
Neuro Oncol; 2016 Feb; 18(2):283-90. PubMed ID: 26691210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
